Boston Scientific (NYSE:BSX) Director David Habiger Acquires 2,100 Shares

Key Points

• Director David Habiger bought 2,100 Boston Scientific shares at an average price of $47.59, investing nearly $100,000 and increasing his holdings by 13.94% to 17,160 shares.
• Boston Scientific exceeded quarterly expectations, reporting $0.86 EPS and $5.44 billion in revenue, while revenue increased 7.5% year over year. The company also authorized a $5 billion share-repurchase plan.
• Analysts maintain a “Moderate Buy” consensus rating, with 24 Buy ratings and a consensus price target of $71.62, despite several firms recently lowering their targets.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) Director David Habiger bought 2,100 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $0.05 during trading on Friday, reaching $49.35. The company's stock had a trading volume of 11,443,129 shares, compared to its average volume of 18,379,627. The company has a quick ratio of 1.22, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company has a market capitalization of $71.53 billion, a P/E ratio of 19.98, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The business has a 50 day moving average price of $45.73 and a 200-day moving average price of $60.81.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the company posted $0.75 earnings per share. Boston Scientific's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of research firms recently commented on BSX. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Barclays dropped their target price on shares of Boston Scientific from $96.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 28th. Bank of America decreased their price target on Boston Scientific from $105.00 to $68.00 and set a "buy" rating on the stock in a research note on Monday, May 18th. UBS Group lowered their price target on Boston Scientific from $74.00 to $67.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Finally, TD Cowen dropped their price objective on Boston Scientific from $61.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $71.62.

Hedge Funds Weigh In On Boston Scientific

Hedge funds have recently added to or reduced their stakes in the business. Outfitters Financial LLC increased its holdings in shares of Boston Scientific by 0.5% during the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider's stock worth $2,291,000 after purchasing an additional 110 shares during the period. Natural Investments LLC grew its position in Boston Scientific by 2.9% during the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider's stock worth $384,000 after buying an additional 112 shares in the last quarter. Patton Fund Management Inc. grew its position in Boston Scientific by 5.5% during the fourth quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider's stock worth $217,000 after buying an additional 118 shares in the last quarter. Bridgewater Advisors Inc. increased its stake in Boston Scientific by 1.2% during the 4th quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider's stock worth $921,000 after acquiring an additional 123 shares during the period. Finally, CYBER HORNET ETFs LLC increased its stake in Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider's stock worth $391,000 after acquiring an additional 132 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source